Skip to main content
. 2023 Feb 24;9(3):e13763. doi: 10.1016/j.heliyon.2023.e13763

Table 2b.

General primary outcomes from clinical trials

Primary outcomes Heparin Rivaroxaban Apixaban Edoxaban Dabigatran Warfarin
Thrombotic events 6 1 0 0 0 0
Mortality 38 7 2 3 1 1
ICU admission 11 0 0 0 0 0
Hospitalization 9 7 1 0 0 0
Ventilation 47 7 2 0 0 0
PaO2/FiO2 ratio 6 0 0 0 0 0